CLINICAL RESEARCH: CLINICAL TRIALS
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein
The PIOSTAT Study
Markolf Hanefeld, MD, PhD*,*,
Nikolaus Marx, MD ,
Andreas Pfützner, MD, PhD ,
Werner Baurecht, MSc ,
Georg Lübben, MD||,
Efstrathios Karagiannis, MD||,
Ulf Stier, MD* and
Thomas Forst, MD
* GWT, Center for Clinical Studies, Dresden, Germany
University Ulm, Medical Department II, Ulm, Germany
Institute for Clinical Research and Development, Mainz, Germany
Acromion, Frechen, Germany
|| Takeda Pharma, Aachen, Germany
Manuscript received April 11, 2006;
revised manuscript received August 24, 2006,
accepted August 28, 2006.
* Reprint requests and correspondence: Dr. Markolf Hanefeld, Forschungshereich Endokrinologie and Stoffwechsel, Zentrum für Klinische Studien, GWT-TUD mbH, Fiedlerstrasse 34, 01307 Dresden, Germany. (Email: hanefeld{at}gwtonline-zks.de).
OBJECTIVES: The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive protein (hs-CRP) levels.
BACKGROUND: Low-grade inflammation is a pathogenic factor for atherosclerosis. High-sensitivity CRP, matrix metalloproteinase (MMP)-9, and plasminogen activator inhibitor (PAI)-1 are markers of inflammation. Statins and peroxisome proliferator-activated receptor (PPAR)- agonists lower inflammatory markers and reduce CVD in type 2 diabetes.
METHODS: In a 12-week, prospective, double-blind trial, 125 subjects were randomized to simvastatin or pioglitazone plus placebo or a simvastatin/pioglitazone combination. We tested changes in hs-CRP by analysis of covariance. A subgroup analysis was performed in patients with and without the metabolic syndrome (MetS). The correlation between changes in hs-CRP and homeostasis model assessment (HOMA; a measure of insulin resistance) was calculated with the Spearman's rank test.
RESULTS: At baseline, there were no significant between-group differences. At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 ± 2.42 mg/l to 2.48 ± 1.77 mg/l and 3.26 ± 2.02 mg/l to 2.81 ± 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 ± 1.97 mg/l to 2.06 ± 1.42 mg/l, p < 0.001). For subgroups, the difference between monotherapy and combination therapy was only significant for simvastatin versus simvastatin plus pioglitazone in patients without MetS. Homeostasis model assessment decreased in those receiving pioglitazone, and the correlation between changes in HOMA and hs-CRP was significant (r = 0.43; p < 0.05). The PAI-1 decreased significantly in the pioglitazone groups only, and MMP-9 was also significantly lowered in the pioglitazone groups. No treatment-related serious adverse events occurred in any group.
CONCLUSIONS: Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin in non-diabetic subjects with CVD and high hs-CRP.
|
Abbreviations and Acronyms
| | CVD = cardiovascular disease | | HOMA = homeostasis model assessment | | hs-CRP = high-sensitivity C-reactive protein | | MCP = macrophage chemoattractant protein | | MetS = metabolic syndrome | | MMPs = matrix metalloproteinases | | PAI = plasminogen activator inhibitor | | PPAR = peroxisome proliferator-activated receptor | | TZD = thiazolidinediones |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 49: A25-A26.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. Gu, X. Liu, X. Wang, H. Shi, H. Tan, L. Zhou, J. Gu, W. Jiang, and Y. Wang
Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus
Europace,
September 1, 2011;
13(9):
1256 - 1261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Dong, W. S. Kerwin, H. Chen, B. Chu, H. R. Underhill, M. B. Neradilek, T. S. Hatsukami, C. Yuan, and X.-Q. Zhao
Carotid Artery Atherosclerosis: Effect of Intensive Lipid Therapy on the Vasa Vasorum--Evaluation by Using Dynamic Contrast-enhanced MR Imaging
Radiology,
July 1, 2011;
260(1):
224 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Furie, S. E. Kasner, R. J. Adams, G. W. Albers, R. L. Bush, S. C. Fagan, J. L. Halperin, S. C. Johnston, I. Katzan, W. N. Kernan, et al.
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke,
January 1, 2011;
42(1):
227 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Hong, S. T. Kim, T.-J. Kim, E.-O. Kim, C.-M. Ahn, J. H. Park, J. S. Kim, K.-M. Lee, and D.-S. Lim
Cellular and Molecular Changes Associated With Inhibitory Effect of Pioglitazone on Neointimal Growth in Patients With Type 2 Diabetes After Zotarolimus-Eluting Stent Implantation
Arterioscler Thromb Vasc Biol,
December 1, 2010;
30(12):
2655 - 2665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Walcher, D. Walcher, J. Hetzel, C. Mielke, M. Rau, K. Rittig, B. Balletshofer, E. Schwedhelm, V. Hombach, R. H. Boger, et al.
Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study
Diabetes and Vascular Disease Research,
July 1, 2010;
7(3):
178 - 185.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Erdmann and R. Wilcox
Pioglitazone and mechanisms of CV protection
QJM,
April 1, 2010;
103(4):
213 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Park, S.-C. Yun, J.-Y. Lee, W.-J. Kim, S.-J. Kang, S.-W. Lee, Y.-H. Kim, C. W. Lee, J.-J. Kim, S.-W. Park, et al.
C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation
Circulation,
November 17, 2009;
120(20):
1987 - 1995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P.B. Ramirez, J. M. Albert, M. J. Blayney, F. Tentori, D. A. Goodkin, R. A. Wolfe, E. W. Young, G. R. Bailie, R. L. Pisoni, and F. K. Port
Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients
J. Am. Soc. Nephrol.,
May 1, 2009;
20(5):
1094 - 1101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Ouellet, S. J. Weisnagel, J. Marois, J. Bergeron, P. Julien, R. Gougeon, A. Tchernof, B. J. Holub, and H. Jacques
Dietary Cod Protein Reduces Plasma C-Reactive Protein in Insulin-Resistant Men and Women
J. Nutr.,
December 1, 2008;
138(12):
2386 - 2391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Forst, B. Wilhelm, A. Pfutzner, W. Fuchs, U. Lehmann, F. Schaper, M. Weber, J. Muller, T. Konrad, and M. Hanefeld
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk
Diabetes and Vascular Disease Research,
November 1, 2008;
5(4):
298 - 303.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. K. McGuire and S. E. Inzucchi
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
Circulation,
January 22, 2008;
117(3):
440 - 449.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. I Katcher, R. S Legro, A. R Kunselman, P. J Gillies, L. M Demers, D. M Bagshaw, and P. M Kris-Etherton
The effects of a whole grain enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome
Am J Clin Nutr,
January 1, 2008;
87(1):
79 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Erdmann
Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk
The British Journal of Diabetes & Vascular Disease,
September 1, 2007;
7(5):
211 - 216.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. A. McAuley, J. I. Mann, J. G. Chase, T. F. Lotz, and G. M. Shaw
Point: HOMA Satisfactory for the Time Being: HOMA: The best bet for the simple determination of insulin sensitivity, until something better comes along
Diabetes Care,
September 1, 2007;
30(9):
2411 - 2413.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Leier and G. J. Haas
Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime
J. Am. Coll. Cardiol.,
July 3, 2007;
50(1):
37 - 39.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, A. M. Skene, and on behalf of the PROactive Investigators
The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction: Results From the PROactive (PROactive 05) Study
J. Am. Coll. Cardiol.,
May 1, 2007;
49(17):
1772 - 1780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
